Beijing, China · Founded 2016 · Privately Held (backing)
Operator of an innovative pharmaceutical company intended to be specialized in innovative drug research, clinically valuable generic drug development and pharmaceutical industrialization. PrimeGene (Beijing) is based in Beijing, China and was founded in 2016. Its last reported valuation was $248 million in Jan 2025. It has raised $85.6 million.
Last reported valuation
$248.0M
Oct 2026
Priced at
—
Total raised
$85.6M
Last round
—
Cap table — not yet on record
PrimeGene (Beijing)'s share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of PrimeGene (Beijing) with a free account
·Watch PrimeGene (Beijing): the Monday email on marks, rounds and moves
